{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:57:04Z","timestamp":1789696624759,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine: X"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.cytox.2022.100063","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T20:54:02Z","timestamp":1642452842000},"page":"100063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["An exploratory study of circulating cytokines and chemokines in patients with muscle disorders proposes CD40L and CCL5 represent general disease markers while CXCL10 differentiates between patients with an autoimmune myositis"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9403-4401","authenticated-orcid":false,"given":"Boel","family":"De Paepe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken R.","family":"Bracke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan L.","family":"De Bleecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytox.2022.100063_b0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current Classification and Management of Inflammatory Myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.cytox.2022.100063_b0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"Immune-Mediated Necrotizing Myopathies Working Group 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.cytox.2022.100063_b0015","article-title":"Statin-induced immune-mediated necrotizing myopathy: an increasingly recognized inflammatory myopathy","volume":"12","author":"Stroie","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.cytox.2022.100063_b0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000513","article-title":"Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy","volume":"6","author":"Lim","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.cytox.2022.100063_b0025","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1212\/01.wnl.0000192128.13875.1e","article-title":"Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition","volume":"66","author":"Askanas","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.cytox.2022.100063_b0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cyto.2018.02.012","article-title":"Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity","volume":"109","author":"Karin","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.cytox.2022.100063_b0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2008.12.002","article-title":"CXCL10 and autoimmune diseases","volume":"8","author":"Lee","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cytox.2022.100063_b0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-170234","article-title":"Cytokine profiling of serum allows monitoring of disease progression in inclusion body myositis","volume":"4","author":"Badrising","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.cytox.2022.100063_b0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/WNL.0000000000001767","article-title":"Plasma IP-10 level distinguishes inflammatory myopathy","volume":"58","author":"Uruha","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.cytox.2022.100063_b0050","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.cytox.2022.100063_b0055","first-page":"1334","article-title":"Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis","volume":"179","author":"Chen","year":"2018","journal-title":"Translat. Res."},{"key":"10.1016\/j.cytox.2022.100063_b0060","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-020-00150-7","article-title":"Serum protein biomarkers for juvenile dermatomyositis: a pilot study","volume":"4","author":"Tawalbeh","year":"2020","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.cytox.2022.100063_b0065","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9079083","article-title":"Role of myokines in myositis pathogenesis and their potential to be new therapeutic targets in idiopathic inflammatory myopathies","author":"Mageriu","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cytox.2022.100063_b0070","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1242\/jcs.066241","article-title":"Chemokine expression and control of muscle cell migration during myogenesis","volume":"123","author":"Griffin","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.cytox.2022.100063_b0075","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s00401-005-0989-5","article-title":"Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies","volume":"109","author":"De Paepe","year":"2005","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cytox.2022.100063_b0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neulet.2012.11.064","article-title":"The nonnecrotic invaded muscle fibers of polymyositis and sporadic inclusion body myositis: On the interplay of chemokines and stress proteins","volume":"535","author":"De Paepe","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cytox.2022.100063_b0085","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/540370","article-title":"Cytokines and chemokines of skeletal muscle inflammation: Presenting the case of Duchenne muscular dystrophy","author":"De Paepe","year":"2013","journal-title":"Med. Inflamm."}],"container-title":["Cytokine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590153222000027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590153222000027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:36:00Z","timestamp":1762914960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590153222000027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2590153222000027"],"URL":"https:\/\/doi.org\/10.1016\/j.cytox.2022.100063","relation":{},"ISSN":["2590-1532"],"issn-type":[{"value":"2590-1532","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An exploratory study of circulating cytokines and chemokines in patients with muscle disorders proposes CD40L and CCL5 represent general disease markers while CXCL10 differentiates between patients with an autoimmune myositis","name":"articletitle","label":"Article Title"},{"value":"Cytokine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytox.2022.100063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100063"}}